PressApril 3, 2025 Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing
PressApril 3, 2025 Filament Health Reports Q4 and Year End 2024 Financial Results and Operational Highlights
PressApril 3, 2025 Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
PressMarch 27, 2025 Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein
PressMarch 27, 2025 Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients
PressMarch 27, 2025 Atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
PressMarch 27, 2025 Numinus Approved as a State-Certified Natural Medicine Training Program in Colorado
PressMarch 20, 2025 Neural Therapeutics Commences Trading, Provides Update on Growth Initiatives and Engages Investor Relations Consultants
PressMarch 20, 2025 Filament Health Announces Positive Data From Phase 2 Study of PEX010 in Patients With Alcohol Use Disorder
PressMarch 20, 2025 Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
PressMarch 20, 2025 atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
PressMarch 20, 2025 Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea
